Acetylon Pharmaceuticals Secures $15,000,000 New Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=032759aa-310f-43e1-b51d-19a5acebd36e&Preview=1 - Date
2/9/2012 - Company Name
Acetylon Pharmaceuticals - Mailing Address
70 Fargo Street Boston, MA 02210 - Company Description
Acetylon Pharmaceuticals is a Boston-based company recently formed to commercialize promising pharmaceutical technology emerging from collaborative research at Harvard University and the Dana-Farber Cancer Institute. Acetylon intends to pursue the clinical development and commercialization of next generation, selective, small-molecule Histone Deacetylase (HDAC) inhibitors with enhanced therapeutic effectiveness and tolerability versus current alternatives. - Website
http://www.acetylon.com - Transaction Type
Venture Equity - Transaction Amount
$15,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
Acetylon’s scientists plan to test ACY-1215 in combination with bortezomib (Velcade), made by Millennium Pharmaceuticals. - M&A Terms
- Venture Investor
Celgene Corporation
